Enrollment in Phase 3 Masitinib Trial Expected to Soon Resume in France

Enrollment in Phase 3 Masitinib Trial Expected to Soon Resume in France

299846

Enrollment in Phase 3 Masitinib Trial Expected to Soon Resume in France

AB Science’s proposed measures to ensure patient safety in clinical trials of its experimental oral therapy masitinib were deemed sufficient by the French National Agency for Medicines and Health Products Safety (ANSM), and patient enrollment in the country may resume. The announcement comes less than two months after the company temporarily suspended recruitment and treatment in all masitinib trials, after a potential risk of ischemic heart disease — a condition of recurring chest pain or discomfort…

You must be logged in to read/download the full post.